Hepatitis C virus and depression in drug users

被引:3
作者
Johnson, ME [1 ]
Fisher, DG [1 ]
Fenaughty, A [1 ]
Theno, SA [1 ]
机构
[1] Univ Alaska, Dept Psychol, IVDU Project, Anchorage, AK 99508 USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: Clinical case studies have implicated depression as a possible side-effect of interferon treatment for the Hepatitis C virus (HCV), However, because these studies generally did not include a pretreatment assessment of depression, it cannot be definitively stated whether depression is a side-effect of interferon treatment, a syndrome coexisting with HCV, or a common characteristic of individuals who are vulnerable to HCV infection. To gather more information about this issue, self-reported depressive symptomatology of drug users with HCV who have not received interferon treatment was compared to that of uninfected drug users. Methods: Subjects were 309 drug users not currently in substance abuse treatment who were participating in a National institute on Drug Abuse project, Subjects completed the Center for Epidemiological Studies-Depression (CES-D) instrument and provided a blood sample for HCV testing. Results: Serological findings revealed that 52.4% of the subjects tested positive for HCV antibodies. Of the HCV-positive subjects, 57.2% had significant depressive symptomatology, whereas only 48.2% of the HCV-negative subjects did, for an overall rate of 52.6%. The two groups also differed on two specific dimensions of depression, with the HCV-positive group scoring lower on the Positive Affect scale and higher on the Somatic/Retarded Activity scale. Conclusions: These findings reveal high levels of depressive symptomatology among drug users, as well as the possibility of a coexisting depressive syndrome with HCV infection. These findings raise the possibility that depression associated with interferon treatment may, at least partially, be accounted for by preexisting depression. Further research is needed to determine the nature and origins of depression in individuals in treatment with interferon for HCV with specific focus placed on determining the dimensions of depression associated with HCV infection and interferon treatment. (C) 1998 by Am. Cell. of Gastroenterology.
引用
收藏
页码:785 / 789
页数:5
相关论文
共 31 条
  • [1] NEUROPSYCHIATRIC MANIFESTATIONS OF HUMAN-LEUKOCYTE INTERFERON THERAPY IN PATIENTS WITH CANCER
    ADAMS, F
    QUESADA, JR
    GUTTERMAN, JU
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (07): : 938 - 941
  • [2] RISK-FACTORS FOR ACUTE NON-A, NON-B HEPATITIS IN THE UNITED-STATES AND ASSOCIATION WITH HEPATITIS-C VIRUS-INFECTION
    ALTER, MJ
    HADLER, SC
    JUDSON, FN
    MARES, A
    ALEXANDER, WJ
    HU, PY
    MILLER, JK
    MOYER, LA
    FIELDS, HA
    BRADLEY, DW
    MARGOLIS, HS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (17): : 2231 - 2235
  • [3] [Anonymous], 1991, RISK BEH ASS
  • [4] [Anonymous], [No title captured], DOI DOI 10.1016/B978-0-12-450660-2.50011-2
  • [5] HEPATITIS-C VIRUS IN INTRAVENOUS-DRUG-USERS
    BELL, J
    BATEY, RG
    FARRELL, GC
    CREWE, EB
    CUNNINGHAM, AL
    BYTH, K
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1990, 153 (05) : 274 - 276
  • [6] HEPATITIS-C VIRUS-INFECTION AMONG A COHORT OF VICTORIAN INJECTING DRUG-USERS
    CROFTS, N
    HOPPER, JL
    BOWDEN, DS
    BRESCHKIN, AM
    MILNER, R
    LOCARNINI, SA
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1993, 159 (04) : 237 - 241
  • [7] Dowling-Guyer S, 1994, ASSESSMENT, V1, P383, DOI DOI 10.1177/107319119400100407
  • [8] Hepatitis C virus infection among Alaskan drug users
    Fisher, DG
    Fenaughty, AM
    Paschane, AA
    Paschane, DM
    Cagle, HH
    Orr, SM
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1997, 87 (10) : 1722 - 1724
  • [9] FISHER DG, 1993, 11 INT C AIDS BERL G
  • [10] FISHER DG, 1993, 121 ANN AM PUBL HLTH, V2072, P143